(Q39704048)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Sze Chuen Cesar Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Brigette Ma

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Anthony Tak-Cheung Chan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Edwin Pun Hui

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Cecilia P Y Lau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Crystal S F Cheung

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kakiu Ho

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Suk-Hang Cheng

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Margaret H L Ng

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

1 reference

15 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1123-1131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

Pathogenesis and treatment of nasopharyngeal carcinoma.

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/HK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Expression of HER2 and C-KIT in Nasopharyngeal Carcinoma: Implications for a New Therapeutic Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9451-1

Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470).

21 January 2018

1 reference

12 December 2020

The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma

1 reference

12 December 2020

Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505

1 reference

12 December 2020

Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma

1 reference

12 December 2020

Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer

1 reference

12 December 2020

[Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma]

1 reference

12 December 2020

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

1 reference

12 December 2020

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma

1 reference

12 December 2020

Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival

1 reference

12 December 2020

Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group

1 reference

12 December 2020

STI571 sensitizes nasopharyngeal carcinoma cells to cisplatin: sustained activation of ERK with improved growth inhibition

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.

1 reference

12 December 2020

Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic-cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents

1 reference

9 March 2024

https://opencitations.net/index/api/v1/citations/10.1002/IJC.22945

Identifiers

DOI

10.1007/S10637-010-9451-1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467883%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference